Observational Evaluation of Atopic Dermatitis in Pediatric Patients

Condition(s) studied

Investigational drug(s) / intervention(s)

Standard of care: Treatment as per standard practice

Study summary

Primary Objectives:

* To describe the characteristics of pediatric patients with moderate to severe atopic dermatitis (AD) whose disease is not adequately controlled with topical therapies or when those therapies are not medically advisable.
* To evaluate the time-course of AD and selected atopic comorbidities.

Secondary Objectives:

* To characterize disease burden and unmet need.
* To describe real-world treatment patterns (eg, dosing regimens, treatment duration, and reasons for discontinuation and/or switching).
* To document the real-world effectiveness and safety of treatments.

Eligibility

Primary outcome measure(s)

• Patient demographics — Baseline (Month 0)
• Medical history of selected atopic diseases and comorbidities — Baseline (Month 0)
• Age at onset of atopic dermatitis (AD) — Baseline (Month 0)
• Personal and family history of AD and selected atopic diseases — Baseline (Month 0)
• All prior and current systemic AD treatment — Baseline (Month 0)
• All prior and current topical therapy and phototherapy for AD (including dose, route and frequency of administration for all AD treatment) — Baseline (Month 0)
• Presence/severity of AD and selected atopic comorbid conditions — Baseline to Month 120
• Therapy for selected atopic comorbid conditions — Baseline to Month 120

Trial sites (182)

+ 142 more sites — see the full list on the official registry below.

More Sanofi trials in China

Other trials for the same condition